Literature DB >> 33907576

Comprehensive genomic analysis contrasting primary colorectal cancer and matched liver metastases.

Akio Shiomi1,2, Masatoshi Kusuhara3, Takashi Sugino4, Teiichi Sugiura5, Keiichi Ohshima6, Takeshi Nagashima7,8, Kenichi Urakami7, Masakuni Serizawa9, Hideyuki Saya2, Ken Yamaguchi10.   

Abstract

Recent studies have revealed that colorectal cancer (CRC) displays intratumor genetic heterogeneity, and that the cancer microenvironment plays an important role in the proliferation, invasion and metastasis of CRC. The present study performed genomic analysis on paired primary CRC and synchronous colorectal liver metastasis (CRLM) tissues collected from 22 patients using whole-exome sequencing, cancer gene panels and microarray gene expression profiling. In addition, immunohistochemical analysis was used to confirm the protein expression levels of genes identified as highly expressed in CRLM by DNA microarray analysis. The present study identified 10 genes that were highly expressed in CRLM compared with in CRC, from 36,022 probes obtained from primary CRC, CRLM and normal liver tissues by gene expression analysis with DNA microarrays. Of the 10 genes identified, five were classified as encoding 'matricellular proteins' [(osteopontin, periostin, thrombospondin-2, matrix Gla protein (MGP) and glycoprotein nonmetastatic melanoma protein B (GPNMB)] and were selected for immunohistochemical analysis. Osteopontin was strongly expressed in CRLM (6 of 22 cases: 27.3%), but not in CRC (0 of 22: 0%; P=0.02). Periostin also exhibited strong immunoreactivity in CRLM (17 of 22: 68.2%) compared with in CRC (7 of 22: 31.8%; P=0.006). Thrombospondin-2 exhibited strong immunoreactivity in both CRC and CRLM (54.5% in CRC, 45.5% in CRLM; P=0.55). GPNMB and MGP were rarely positive for both CRC and CRLM. A comparison of immunoreactive positive factors for these five genes revealed the complexities of gene expression in CRLM. Of the cases examined, 16 (72.7%) cases of CRC showed zero or only one positive immunoreactive factor. By contrast, CRLM showed more frequent and multiple immunoreactive factors; for example, 16 cases (72.7%) shared two or more factors, which was statistically more frequent than in CRC (P=0.007). The present study revealed the genomic heterogeneity between paired primary CRC and CRLM, in terms of cancer cell microenvironment. This finding may lead to novel diagnostic and therapeutic targets in the era of genome-guided personalized cancer treatment.
Copyright © 2021, Spandidos Publications.

Entities:  

Keywords:  colorectal cancer; gene expression; heterogeneity; liver metastasis; microenvironment

Year:  2021        PMID: 33907576      PMCID: PMC8063276          DOI: 10.3892/ol.2021.12727

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  66 in total

1.  Comparative genomic analysis of primary versus metastatic colorectal carcinomas.

Authors:  Efsevia Vakiani; Manickam Janakiraman; Ronglai Shen; Rileen Sinha; Zhaoshi Zeng; Jinru Shia; Andrea Cercek; Nancy Kemeny; Michael D'Angelica; Agnes Viale; Adriana Heguy; Philip Paty; Timothy A Chan; Leonard B Saltz; Martin Weiser; David B Solit
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

Review 2.  Osteopontin.

Authors:  J Sodek; B Ganss; M D McKee
Journal:  Crit Rev Oral Biol Med       Date:  2000

3.  Integrated next-generation sequencing analysis of whole exome and 409 cancer-related genes.

Authors:  Yuji Shimoda; Takeshi Nagashima; Kenichi Urakami; Tomoe Tanabe; Junko Saito; Akane Naruoka; Masakuni Serizawa; Tohru Mochizuki; Keiichi Ohshima; Sumiko Ohnami; Shumpei Ohnami; Masatoshi Kusuhara; Ken Yamaguchi
Journal:  Biomed Res       Date:  2016       Impact factor: 1.203

4.  Role of periostin in cancer progression and metastasis: inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model.

Authors:  Mariko Kyutoku; Yoshiaki Taniyama; Naruto Katsuragi; Hideo Shimizu; Yasuo Kunugiza; Kazuma Iekushi; Nobutaka Koibuchi; Fumihiro Sanada; Yoshihiro Oshita; Ryuichi Morishita
Journal:  Int J Mol Med       Date:  2011-05-26       Impact factor: 4.101

5.  Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues.

Authors:  H Nemoto; S R Rittling; H Yoshitake; K Furuya; T Amagasa; K Tsuji; A Nifuji; D T Denhardt; M Noda
Journal:  J Bone Miner Res       Date:  2001-04       Impact factor: 6.741

6.  Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.

Authors:  Chien-Tsun Kuan; Kenji Wakiya; Jeannette M Dowell; James E Herndon; David A Reardon; Michael W Graner; Gregory J Riggins; Carol J Wikstrand; Darell D Bigner
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

Review 7.  Thrombospondins and tumor angiogenesis.

Authors:  F de Fraipont; A C Nicholson; J J Feige; E G Van Meir
Journal:  Trends Mol Med       Date:  2001-09       Impact factor: 11.951

8.  ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties.

Authors:  April A N Rose; Matthew G Annis; Zhifeng Dong; Francois Pepin; Michael Hallett; Morag Park; Peter M Siegel
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

9.  ClinVar: public archive of relationships among sequence variation and human phenotype.

Authors:  Melissa J Landrum; Jennifer M Lee; George R Riley; Wonhee Jang; Wendy S Rubinstein; Deanna M Church; Donna R Maglott
Journal:  Nucleic Acids Res       Date:  2013-11-14       Impact factor: 16.971

10.  The consensus molecular subtypes of colorectal cancer.

Authors:  Justin Guinney; Rodrigo Dienstmann; Xin Wang; Aurélien de Reyniès; Andreas Schlicker; Charlotte Soneson; Laetitia Marisa; Paul Roepman; Gift Nyamundanda; Paolo Angelino; Brian M Bot; Jeffrey S Morris; Iris M Simon; Sarah Gerster; Evelyn Fessler; Felipe De Sousa E Melo; Edoardo Missiaglia; Hena Ramay; David Barras; Krisztian Homicsko; Dipen Maru; Ganiraju C Manyam; Bradley Broom; Valerie Boige; Beatriz Perez-Villamil; Ted Laderas; Ramon Salazar; Joe W Gray; Douglas Hanahan; Josep Tabernero; Rene Bernards; Stephen H Friend; Pierre Laurent-Puig; Jan Paul Medema; Anguraj Sadanandam; Lodewyk Wessels; Mauro Delorenzi; Scott Kopetz; Louis Vermeulen; Sabine Tejpar
Journal:  Nat Med       Date:  2015-10-12       Impact factor: 53.440

View more
  3 in total

Review 1.  The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer.

Authors:  Alisha Bent; Shreya Raghavan; Arvind Dasari; Scott Kopetz
Journal:  Clin Colorectal Cancer       Date:  2022-03-26       Impact factor: 4.035

2.  TROP2 Represents a Negative Prognostic Factor in Colorectal Adenocarcinoma and Its Expression Is Associated with Features of Epithelial-Mesenchymal Transition and Invasiveness.

Authors:  Jiří Švec; Monika Šťastná; Lucie Janečková; Dušan Hrčkulák; Martina Vojtěchová; Jakub Onhajzer; Vítězslav Kříž; Kateřina Galušková; Eva Šloncová; Jan Kubovčiak; Lucie Pfeiferová; Jan Hrudka; Radoslav Matěj; Petr Waldauf; Lukáš Havlůj; Michal Kolář; Vladimír Kořínek
Journal:  Cancers (Basel)       Date:  2022-08-26       Impact factor: 6.575

Review 3.  Targeting Metastatic Colorectal Cancer with Immune Oncological Therapies.

Authors:  Norman J Galbraith; Colin Wood; Colin W Steele
Journal:  Cancers (Basel)       Date:  2021-07-16       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.